Diagnosis and management of antiphospholipid syndrome [Erratum]

Ahn Y, Hawkins C, Pearson E, Kubler P. Diagnosis and management of antiphospholipid syndrome. Aust Prescr 2024;47:179-85. https://doi.org/10.18773/austprescr.2024.055

In the article, it was stated “As low-molecular-weight heparin is associated with an increased risk of osteoporosis, it is important to minimise the treatment duration of this drug to a maximum of 12 weeks”.

This has been amended to “As low-molecular-weight heparin is associated with an increased risk of osteoporosis, it is important to limit the treatment duration of this drug to a maximum of 12 weeks postpartum (in addition to the duration of pregnancy)”.

The correction to the text has been made to the HTML and PDF versions of this article.

We apologise for the error and any confusion it might have caused our readers.

View the corrected version of the article.